You are here: Home » Markets » News
Business Standard

Granules India up 5% on USFDA approval for generic Aleve PM tablets

According to media reports, global private equity firms have expressed interest in acquiring a controlling stake in the company

Granules India | Buzzing stocks | Markets

SI Reporter  |  Mumbai 

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Representative image

Shares of gained 5 per cent at Rs 377 on the BSE on Friday after US health regulator USFDA gave its approval for Naproxen Sodium and Diphenhydramine Hydrochloride Tablets, 220 mg/25 mg (OTC).

The company today announced that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Naproxen Sodium and Diphenhydramine Hydrochloride Tablets, 220 mg/25 mg (OTC), generic equivalent of Aleve PM Tablets, 220 mg/25 mg, of Bayer HealthCare LLC.

Naproxen Sodium and Diphenhydramine Hydrochloride Tablets are used for relief of occasional sleeplessness associated with minor aches and pains.

Granules now has a total of 31 ANDA approvals from US FDA (29 Final approvals and 2 tentative approvals). The Company produces Finished Dosages (FDs}, Pharmaceutical Formulation intermediates (PFls) and Active Pharmaceutical Ingredients (APIs).

Meanwhile, the pharmaceutical company's stock hit a record high of Rs 395, after rallying 10 per cent in the opening deals on report that that global private equity firms Blackstone, KKR and Bain Capital have expressed interest in acquiring a controlling stake in the company.

The BSE has sought clarification from the company on the said report.

The company said the promoters released 12.95 per cent pledged shares during the April-June quarter; 3.64 per cent of the total shareholder’s equity remains currently pledged.

At 12:17 pm the stock was trading 4.4 per cent higher at Rs 377 on the BSE, against 1.7 per cent rise in the S&P BSE Sensex. A combined around 6.2 million shares have changed hands on the counter on the NSE and BSE, so far.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, September 25 2020. 12:20 IST